Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Annals of Surgical Oncology|July 2, 2016
The Impact of Neoadjuvant Treatment on Surgical Options and OutcomesBeyhan Ataseven, Gunter von Minckwitz
Breast Care (Basel, Switzerland)|April 7, 2016
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureMattea Reinisch, Beyhan Ataseven, Sherko Kümmel
Plos One|June 6, 2012
BRCA2 mutations and triple-negative breast cancerPeter Meyer, Katharina Landgraf, Bernhard Högel, et al.
Gynecologic Oncology|June 24, 2016
FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisitedBeyhan Ataseven, Luis M Chiva, Philipp Harter, et al.
Gynecologic Oncology Reports|February 16, 2022
Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experienceMalak Moubarak, Philipp Harter, Beyhan Ataseven, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification CharacteristicsBeyhan Ataseven, Daniela Gologan, Angela Gunesch, et al.
Gynecologic Oncology|October 15, 2014
Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancerBeyhan Ataseven, Christoph Grimm, Philipp Harter, et al.
Cancer|January 23, 2020
How to manage lymph nodes in ovarian cancerPhilipp Harter, Florian Heitz, Beyhan Ataseven, et al.
Gynecologic Oncology|December 23, 2015
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IVBeyhan Ataseven, Christoph Grimm, Philipp Harter, et al.
Oncotargets and Therapy|October 23, 2014
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugsBeyhan Ataseven, Angela Gunesch, Wolfgang Eiermann, et al.
Pageof 11